Lytix Biopharma ASA · OSL:LYTIX

Lytix Biopharma ASA — Q3 2025 Earnings Presentation

32 slides from Lytix Biopharma ASA's earnings presentation, November 2025

  1. Slide 1: Oncolytic Molecules that Kill Cancer & Prevent Recurrence

    Oncolytic Molecules that Kill Cancer & Prevent Recurrence Neoadjuvant Immunotherapy with Durable Responses Approaching Commercialization Q3 Earnings Presentation November 2025

  2. Slide 2: Disclaimer

    Disclaimer This presentation (the "Presentation") has been prepared by Lytix Biopharma AS ("Company") exclusively for information purposes. The Presentation is being made only to, and is only directed at, persons to whom such presentation may lawfully be communicated (’relevant persons’). Any person

  3. Slide 3: Presenting team

    Presenting team Øystein Rekdal, CEO Gjest Breistein, CFO Founder and scientist-CEO with over two Finance leader with strong track decades in immuno-oncology, leading the record in listed companies, ensuring discovery and development of Lytix’s disciplined financial management innovative peptide-base

  4. Slide 4: Company introduction

    Company introduction Company Overview 4 Non-confidential

  5. Slide 5: Lytix's Therapies Work Through a Two-Phase Mechanism

    Lytix’s Therapies Work Through a Two-Phase Mechanism; Killing Tumors Locally & Activating Broad Systemic Immune Response 5

  6. Slide 6: Lytix Biopharma is Rapidly Approaching Commercialization of Ruxotemitide in the Neoadjuvant Setting

    Lytix Biopharma is Rapidly Approaching Commercialization of Ruxotemitide in the Neoadjuvant Setting Ruxotemitide has strong potential for resectable solid tumors in a neoadjuvant setting Intratumoral Injections with Abscopal Effects Highly Synergistic with Current SOC • Direct tumor injections induc

  7. Slide 7: Current Treatment Options for Resectable Tumors Carry High Risk of Recurrence or Low Response Rate

    Current Treatment Options for Resectable Tumors Carry High Risk of Recurrence or Low Response Rate Treatment Options for Resectable Tumors Lytix’s First-in-Class Solution Surgery: Cancer can be removed but but carries a high Kill cancer cells to induce a strong local risk of recurrence. immune respo

  8. Slide 8: Q3 Highlights

    Q3 Highlights

  9. Slide 9: Highlights for the Third Quarter & Post Quarter End

    Highlights for the Third Quarter & Post Quarter End Verrica Partnership – Advancing Ruxotemitide (VP-315) Toward Phase III in BCC • Positive clinical results from Verrica Pharmaceutical’s current Phase II study in basal cell carcinoma • New data presented at Society for Immunotherapy of Cancer (SITC

  10. Slide 10: Highlights for the Third Quarter & Post Quarter End

    Highlights for the Third Quarter & Post Quarter End LTX-401 – Pipeline Progress • Future development strategy under review to determine optimal timing and pathway for advancement Business and Financial • Q3 financials reflect continued disciplined cost control and stable underlying operating expense

  11. Slide 11: Clinical & Operational Pipeline Overview

    Clinical & Operational 1 Pipeline Overview Phase II study: Basal cell carcinoma 2 (Verrica Pharmaceuticals) 3 NeoLIPA study: Early-stage melanoma 4 LTX-401 11 Non-confidential

  12. Slide 12: Progress Towards Commercialization of Ruxotemitide and Clinical Entry for LTX-401

    Progress Towards Commercialization of Ruxotemitide and Clinical Entry for LTX-401 Population Pre-clinical Phase I Phase II Phase III Partner Ruxotemitide (LTX-315) Monotherapy Basal cell carcinoma Neoadjuvant NeoLIPA resectable melanoma Steadily Recruiting patients LTX-401 Mono-and Solid tumors (dee

  13. Slide 13: Clinical & Operational Pipeline Overview

    Clinical & Operational 1 Pipeline Overview Phase II study: Basal cell carcinoma 2 (Verrica Pharmaceuticals) 3 NeoLIPA study: Early-stage melanoma 4 LTX-401 13 Non-confidential

  14. Slide 14: Verrica Phase II Clinical Results Demonstrate Strong Anti-Tumor Activity with Potential Abscopal Effects

    Verrica Phase II Clinical Results Demonstrate Strong Anti-Tumor Activity with Potential Abscopal Effects Results support continued preparation and fundraising activities for the BCC program • Ruxotemitide (VP-315) was found to be safe and well-tolerated, with no treatment-related serious adverse eve

  15. Slide 15: Exploratory Immune Analysis Demonstrates Reprogramming of Tumors to Overcome Immunosuppression

    Exploratory Immune Analysis Demonstrates Reprogramming of Tumors to Overcome Immunosuppression Findings support ruxotemitide’s potential as a non-surgical, first-line BCC therapy • Immune results presented at Society for Immunotherapy of Cancer (SITC) Annual Meeting - November 2025 • Significant inc

  16. Slide 16: FDA Confirmed Alignment with Verrica's Ph III Program

    FDA Confirmed Alignment with Verrica’s Ph III Program Verrica anticipates Ph III plan will support NDA filing for ruxotemitide in BCC • Phase III program to encompass two placebo-controlled Phase III studies with approximately 100 subjects each and a primary endpoint of complete clearance as assesse

  17. Slide 17: Clinical & Operational Pipeline Overview

    Clinical & Operational 1 Pipeline Overview Phase II study: Basal cell carcinoma 2 (Verrica Pharmaceuticals) 3 NeoLIPA study: Early-stage melanoma 4 LTX-401 17 Non-confidential

  18. Slide 18: NeoLIPA Study Shows Promising Results in Treatment Naïve Melanoma (Phase II)

    NeoLIPA Study Shows Promising Results in Treatment Naïve Melanoma (Phase II) Study Overview • Investigator-initiated study led by Dr. Henrik Jespersen at Oslo University Hospital • Ruxotemitide (intratumoral) + pembrolizumab administered prior to surgery • 13 of 27 patients enrolled as of October 20

  19. Slide 19: NeoLIPA Interim Results Demonstrate Strong Anti-Tumor Activity

    NeoLIPA Interim Results Demonstrate Strong Anti-Tumor Activity Results support accelerated strategic focus on neoadjuvant melanoma • Presented at Nordic Melanoma Meeting – November 2025 • 44% pathological complete response (pCR) and 55% major pathological response (MPR) among the first 9 evaluable p

  20. Slide 20: Clinical & Operational Pipeline Overview

    Clinical & Operational 1 Pipeline Overview Phase II study: Basal cell carcinoma 2 (Verrica Pharmaceuticals) 3 NeoLIPA study: Early-stage melanoma 4 LTX-401 20 Non-confidential

  21. Slide 21: LTX-401 is Approaching Entering the Clinic

    LTX-401 is Approaching Entering the Clinic Future development strategy under review to determine optimal timing & pathway for clinical entry • Proprietary asset of Lytix • Partly validated by ruxotemitide’s clinical results due to same mode-of-action • Positive regulatory feedback supports clinical

  22. Slide 22: Financials & Outlook

    Financials & Outlook 22 Non-confidential

  23. Slide 23: Key Figures – Profit & Loss

    Key Figures – Profit & Loss Amounts in NOK ‘000 Q3 2025 Q3 2024 FY 2024 Total operating income - 231 11,134 Total operating expenses (24,258) (23,280) (107,029) Loss from operations (24,258) (23,049) (95,896) Loss for the period (23,337) (22,738) (94,265) • The Company recorded NOK 11.9 million in n

  24. Slide 24: Lean Cost Base and Solid Runway into 2026

    Lean Cost Base and Solid Runway into 2026 Total operating expenses Cash and short-term financial investments 32,998 130,791 23,280 24,258 21,540 117,903 19,581 20,009* 100,263 13,451 90,005 22,894 5,157 16,315 10,643 10,984* 13,170 60,181 6,277 4,825 50,548 43,539 (3,209) Q4 23 Q1 24 Q2 24 Q3 24 Q4

  25. Slide 25: Key Figures – Balance Sheet

    Key Figures – Balance Sheet Amounts in NOK ‘000 30.09.2025 30.09.2024 31.12.2024 Assets Property, plant and equipment 8 59 42 Right-of-use assets 2,324 2,793 2,589 Trade and other receivables 3,123 9,902 13,113 Short-term financial investments 60,923 - - Cash and cash equivalents 29,082 43,529 130,7

  26. Slide 26: Lytix Biopharma's Roadmap to Create Shareholder Value

    Lytix Biopharma’s Roadmap to Create Shareholder Value Non-metastatic skin cancer Neoadjuvant melanoma Deep seated cancer Ruxotemitide: Clear path Ruxotemitide: Phase II LTX-401: Strong preclinical towards commercialization, results in NeoLIPA results and novel formulation demonstrated through licens

  27. Slide 27: Executing on our Strategy

    Executing on our Strategy Lytix Clinical Development • NeoLIPA topline results 2026 Verrica - BCC • Preparing for pivotal Phase III trial Pipeline & Partnerships • Continued preparations for LTX-401 • Strategic focus on late-stage development & commercialization through partnerships

  28. Slide 28: Q&A

    Q&A 28 Non-confidential

  29. Slide 29: Interim Financial Statements

    Interim Financial Statements 29 Non-confidential

  30. Slide 30: Condensed Interim Statement of Profit & Loss

    Condensed Interim Statement of Profit & Loss Unaudited Unaudited Amounts in NOK thousands Q3 2025 Q3 2024 FY 2024 Revenue - 231 11,134 Other operating income - - - Total operating income - 231 11,134 Payroll and related expenses (15,443) (4,859) (22,590) Depreciation and amortization expenses (252)

  31. Slide 31: Condensed Interim Statement of Financial Position

    Condensed Interim Statement of Financial Position Unaudited Unaudited Amounts in NOK thousands 30.09.2025 30.09.2024 31.12.2024 Assets Non-current assets Property, plant and equipment 8 59 42 Right-of-use assets 2,324 2,793 2,589 Total non-current assets 2,332 2,853 2,631 Current assets Trade and ot

  32. Slide 32: Condensed Interim Statement of Cash Flows

    Condensed Interim Statement of Cash Flows Unaudited Unaudited Amounts in NOK thousands Q3 2025 Q3 2024 FY 2024 Cash flows from operating activities Loss for the period (23,337) (22,738) (94,265) Adjustments for: Depreciation of property, plant and equipment 10 17 68 Depreciation of right-of-use asse

Lytix Biopharma — Q3 2025 Earnings Presentation on 6ix